Article PDF
Avoid common mistakes on your manuscript.
References
Allen LM (1978) The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM26. Drug Metab Rev 8:119
Allen LM (1978) Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4′-demethyl epipodophyllotoxin thenylidene-β-d-glucoside and 4′-demethyl epipodophyllotoxin ethylidene-β-d-glucoside in the L1210 leukemia cell. Cancer Res 38:2549
Allen LM (1980) Analysis of 4′-demethyl epipodophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci 69:1440
Allen LM, Creaven PJ (1975) Comparison of the human pharmacokinetics of VM26 and VP16-213, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697
Allen LM, Marcks C, Creaven PJ (1976) 4′-Demethyl-epipodophyllic acid-9-(4,6-O-ethylidene-β-d-glucopyranoside), the major urinary metabolite of VP16-213 in man. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 17:6
Arnold AM (1979) Podophyllotoxin derivative VP16-213. Cancer Chemother Pharmacol 3:71
Arnold AM, Dodson M, Renwick A, Whitehouse JMA (1980) Pharmacokinetics of VP16-213 using a new HPLC assay. Cancer Chemother Pharmacol (Suppl) 5:2
Bleyer WA, Krivit W, Chard RL Jr, Hammond D (1979) Phase II study of VM26 in acute leukemia, neuroblastoma and other refractory childhood malignancies: A report from the children's cancer study group. Cancer Treat Rep 63:977
Brunner KW, Sonntag RW, Ryssel HJ, Cavalli F (1976) Comparison of the biologic activity of VP16-213 given IV and orally in capsules or drink ampules. Cancer Treat Rep 60:1377
Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW (1978) VP16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473
Creaven PJ, Allen LM (1975) EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:221
Creaven PJ, Allen LM (1975) PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:227
Creaven PJ, Newman SJ, Selawry OS, Cohen MH, Primack A (1974) Phase I clinical trial of weekly administration of 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-d-glucopyranoside) (NSC 141540; VP16-213). Cancer Chemother Rep 58:901
D'Incalci M, Farina P, Fasoli M, Marsoni S (1981) VP16-213 plasma levels after I.V. and two methods of oral administration to choriocarcinoma patients. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:357
Evans WE, Sinkule JA, Horvath A, Crom WR, Dow LW, Rivera G (1981) Clinical pharmacology of VM26 (NSC 122819) and VP16-213 (NSC 141540) in children with cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:174
Falkson G, Van Dyk JJ, Van Eden EB, Van Der Merwe AM, Van Den Bergh JA, Falkson HC (1975) A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-d-ethylidene glucoside (NSC 141540) VP16-213. Cancer 35:1141
Farina P, Marzillo G, D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethyl-epipo-dophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) (VP16-213) in human plasma. J Chromatogr 222:141
Goldsmith MA, Carter SK (1973) 4′-Demethyl-epipodophyllotoxin-β-d-thenylidene glucoside (VM26). A brief review. Eur J Cancer 9:477
Issell BF, Crooke ST (1979) Etoposide (VP16-213). Cancer Treat Rev 6:107
Knott GD, Reece DK (1972) MLAB: a civilized curve-fitting system. Proc On-Line 1:497
Lau ME, Hansen HH, Nissen NI, Pedersen H (1979) Phase I trial of a new form of an oral administration of VP16-213. Cancer Treat Rep 63:485
Madajewicz S, West CR, Park HC, Avellanosa AM, Caracandas JE, Takita H, Vicent RG, Jennings E (1981) Phase II study of intra-arterial 4-0-demethyl-1-0-(4,6-O-2-thenylidene-β-d-glucopyranosyl) epipodophyllotoxin (VM26) therapy of metastatic bronchogenic adenocarcinoma to the brain. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:502
Metzler CM (1969) NONLIN, Tech Rep No 7292/69-7293/005 Upjohn, Michigan
Muggia FM, Selawry OS, Hansen HH (1971) Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-β-d-glucopyranoside) (NSC 122819). Cancer Chemother Rep 55:575
Nissen NI, Dombernowsky P, Hansen HH, Larsen V (1976) Phase I clinical trial of an oral solution of VP16-213. Cancer Treat Rep 60:943
Nissen NI, Hansen HH, Pedersen H, Stroyer I, Dombernowsky P, Hessellund M (1975) Clinical trial of the oral form of a new podophyllotoxin derivative, VP16-213 (NSC 141540), in patients with advanced neoplastic disease. Cancer Chemother Rep 59:1027
Nissen NI, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new antitumor agent, 4′-demethylepipodo-phyllotoxin 9-(4,6-O-ethylidene-β-d-glucopyranoside) (NSC 141540; VP16-213). Cancer Chemother Rep 56:769
Pelsor FR, Allen LM, Creaven PJ (1978) Multicompartment pharmacokinetic model of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) in humans. J Pharm Sci 67:1106
Radice PA, Bunn PA, Ihde DC (1979) Therapeutic trials with VP16-213 and VM26: Active agents in small cell lung cancer, non-Hodgkins lymphomas and other malignancies. Cancer Treat Rep 63:1231
Rozencweig M, Von Hoff DD, Henney JE, Muggia FM (1977) VM26 and VP16-213. A comparatve analysis. Cancer 40:334
Sandoz Pharmaceuticals, Preclinical Brochure (1967) VM26. Research Department, Hanover New Jersey
Sandoz Pharmaceuticals, Preclinical Brochure (1971) VP16-213. Research Department, Hanover New Jersey
Snodgrass W, Walker L, Heideman R, Odom LF, Hays T, Tubergen DG (1980) Kinetics of VP16-213 epipodophyllotoxin in children with cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 21:333
Spremulli E, Schulz JJ, Speckhart VJ, Wampler GL (1980) Phase II study of VM26 in adult malignancies. Cancer Treat Rep 64:147
Strife RJ, Jardine I, Colvin M (1980) Analysis of the anticancer drugs VP16-213 and VM26 and their metabolites by high performance liquid chromatography. J Chromatogr 182:211
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Creaven, P.J. The clinical pharmacology of VM26 and VP16-213. Cancer Chemother. Pharmacol. 7, 133–140 (1982). https://doi.org/10.1007/BF00254535
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00254535